Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dna X (SONM) EPS (Weighted Average and Diluted) (2022 - 2025)

Dna X's EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$9.44 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$9.44 for Q4 2025, down 126.59% from a year ago — trailing twelve months through Dec 2025 was -$14.98 (down 162.11% YoY), and the annual figure for FY2025 was -$28.58, down 159.82%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$9.44 at Dna X, down from -$4.83 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $35.5 in Q4 2024 to a low of -$9.44 in Q4 2025.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.26 (2023), against an average of $0.53.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 11551.61% in 2024, while the deepest fall reached 7866.67% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.03 in 2022, then tumbled by 1133.33% to -$0.31 in 2023, then surged by 11551.61% to $35.5 in 2024, then crashed by 126.59% to -$9.44 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$9.44, -$4.83, and -$0.79 for Q4 2025, Q3 2025, and Q2 2025 respectively.